Sanofi Genzyme is committed to supporting patients who have been
recently prescribed LIBTAYO for adult patients with metastatic or
locally advanced CSCC
who are not candidates for curative surgery or curative radiation.
The REACH Patient Support Program is designed to provide eligible
patients with services like medication administration,
reimbursement or financial assistance, navigation support, and
education.
The REACH Patient Support Program
is committed to helping your patients get the most out of LIBTAYO
REACH acts as the single point of contact between healthcare professionals and patients, facilitating patient access to LIBTAYO treatment in clinics.
REACH provides support in navigating reimbursement or financial assistance options for patients.
REACH provides patients with treatment education materials before their first dose and are available for any questions related to patient care and treatment.
Learn about the safety and tolerability profile of LIBTAYO in patients with advanced CSCC.
Learn more
Explore the efficacy profile of LIBTAYO, including cases seen from the trials.
Learn more
Learn the details behind Study 1423 and Study 1540, two clinical trials used to evaluate the efficacy and safety profile of LIBTAYO.
Learn more
